FLT-PET/CT对胰腺癌诊断和预后价值的初步研究:与FDG-PET/CT的比较
本研究纳入15例初诊胰腺癌患者,治疗前均行FLT和FDG-PET/CT检查,比较两者检测淋巴结和远处转移的敏感度、特异度和准确率,并分析预后价值。结果显示两种检查检测原发癌和转移灶(肝转移除外)的效能无显著差异,FLT-SUVmax提供最显著的预后信息。
要点
- FLT-PET/CT与FDG-PET/CT检测淋巴结转移的敏感度、特异度、准确率相同,分别为63.6%、100%、73.3%。
- FDG-PET/CT检测远处转移敏感度100%,FLT-PET/CT为50.0%;4例多发性肝转移中FDG均阳性而FLT有3例阴性。
- FLT-SUVmax是与无进展生存期和总生存期均相关的预后因素,且对总生存期的预测优于FDG-TLG或FLT-TLP。
核心结论
- FLT-PET/CT检测原发癌和转移癌(肝转移除外)的效能可能与FDG-PET/CT相当,FLT-SUVmax可提供最显著的预后信息。
研究设计与样本
- 初步研究,纳入15例初诊胰腺癌患者,治疗前均行FLT和FDG-PET/CT扫描;采用McNemar精确检验或χ²检验比较两组检测淋巴结和远处转移的敏感度、特异度、准确率,Kaplan-Meier法计算无进展生存期和总生存期,Cox比例风险分析评估预后意义。
关键影像表现/征象
- 两种扫描均显示全部原发癌。
- 4例多发性肝转移患者中,FDG-PET/CT全部阳性,FLT-PET/CT有3例阴性。
诊断标准与关键数值
- 检测淋巴结转移(按患者分析):两种扫描敏感度均为63.6%(7/11)、特异度均为100%(4/4)、准确率均为73.3%(11/15),两者间无显著差异(p>0.05)。
- 检测远处转移(按患者分析):FDG-PET/CT敏感度100%(6/6)、特异度88.9%(8/9)、准确率93.3%(14/15);FLT-PET/CT敏感度50.0%(3/6)、特异度100%(9/9)、准确率80.0%(12/15),两者间无显著差异(p>0.05)。
临床应用与阅片要点
- FLT-PET/CT检测肝转移可能假阴性,4例多发性肝转移中3例FLT阴性而FDG均阳性。
- FLT-SUVmax与无进展生存期相关(单变量分析HR 1.306,p=0.048)。
- FDG-TLG、FLT-SUVmax、FLT-TLP与总生存期相关(p分别为0.021、0.005、0.022)。
- 双变量分析中FLT-SUVmax对总生存期的预测优于FDG-TLG(校正FDG-TLG后HR 1.491,p=0.034)和FLT-TLP(校正FLT-TLP后HR 1.542,p=0.023)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The purpose of the study was to examine the diagnostic and prognostic values of 18F-fluorothymidine (FLT)-PET/CT for pancreatic cancer by comparing with 18F-fluorodeoxyglucose (FDG)-PET/CT.
METHODS: Fifteen patients with newly diagnosed pancreatic cancer underwent both FLT and FDG-PET/CT scans before treatment. The sensitivity, specificity, and accuracy in detecting nodal and distant metastases were compared between both scans using McNemar exact or χ 2 test. Progression-free survival (PFS) and overall survival (OS) were calculated by Kaplan-Meier method. Prognostic significance was assessed by Cox proportional hazards analysis.
RESULTS: Both scans visualized all primary cancers. The sensitivity, specificity, and accuracy per patient basis for detecting nodal metastasis were equal and 63.6% (7/11), 100% (4/4), and 73.3% (11/15) for both scans, and for detecting distant metastasis were 100% (6/6), 88.9% (8/9), and 93.3% (14/15) for FDG-PET/CT, and 50.0% (3/6), 100% (9/9), and 80.0% (12/15) for FLT-PET/CT, respectively, without significant difference in each of them between both scans (p > 0.05). However, of 4 patients with multiple liver metastases, FDG-PET/CT was positive in all, but FLT-PET/CT was negative in three patients. At univariate analysis, only FLT-SUVmax correlated with PFS (hazard ratio, 1.306, p = 0.048), and FDG total lesion glycolysis (TLG), FLT-SUVmax, and FLT-total lesion proliferation (TLP) correlated with OS (p = 0.021, p = 0.005, and p = 0.022, respectively). At bivariate analysis, FLT-SUVmax was superior to FDG-TLG or FLT-TLP for prediction of OS [HR (adjusted for FDG-TLG), 1.491, p = 0.034, HR (adjusted for FLT-TLP), 1.542, p = 0.023].
CONCLUSION: FLT-PET/CT may have a potential equivalent to FDG-PET/CT for detecting primary and metastatic cancers except liver metastasis. FLT-SUVmax can provide the most significant prognostic information.
引用
- Nakajo M, Kajiya Y, Tani A, et al. A pilot study of the diagnostic and prognostic values of FLT-PET/CT for pancreatic cancer: comparison with FDG-PET/CT. Abdom Radiol (NY). 2017. PMID: 27891549. doi:10.1007/s00261-016-0987-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。